# FDA advisory committee calendar

Canonical: https://sec-api.dev/adcom-calendar

> No FDA advisory committee meetings for tracked drugs are scheduled in the next 90 days. No drug or biologic advisory committee meeting is scheduled on the FDA calendar or in a Federal Register notice. (FDA advisory committee calendar and Federal Register checked 2026-11-16 22:20 UTC)

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Meetings

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| July 30, 2026 | [Vusolimogene oderparepvec FDA advisory committee meeting](https://sec-api.dev/pdufa/vusolimogene-oderparepvec) | REPL |  | completed | "On July 30, 2026, the Committee will meet in open session to discuss and make recommendations on Biologics License Application (BLA) 125827, from Replimune, Inc. for vusolimogene oderparepvec. The proposed indication (use) is in combination with nivolumab for the treatment of adult patients with advanced melanoma who have previously received an anti-PD-1 containing regimen." ([FDA advisory committee calendar](https://www.fda.gov/advisory-committees/advisory-committee-calendar/cellular-tissue-and-gene-therapies-advisory-committee-july-30-2026-meeting-announcement-updated)) |
| July 29, 2026 | [Deramiocel FDA advisory committee meeting](https://sec-api.dev/pdufa/deramiocel) | CAPR | treatment of cardiomyopathy in Duchenne muscular dystrophy (DMD) | completed, mixed | "On July 29, 2026, the Committee will meet in open session to discuss and make recommendations on Biologics License Application (BLA) 125842 from Capricor, Inc. for deramiocel (human allogeneic cardiosphere-derived cells) the treatment of cardiomyopathy in Duchenne muscular dystrophy (DMD)." ([FDA advisory committee calendar](https://www.fda.gov/advisory-committees/advisory-committee-calendar/cellular-tissue-and-gene-therapies-advisory-committee-july-29-2026-meeting-announcement-updated)) |
| June 26, 2026 | [Deramiocel FDA advisory committee meeting](https://sec-api.dev/pdufa/deramiocel) | CAPR | Duchenne muscular dystrophy | scheduled | "On June 26, 2026, Capricor Therapeutics, Inc. (the "Company" or "Capricor") issued a press release announcing that the Cellular, Tissue, and Gene Therapies Advisory Committee of the U.S. Food and Drug Administration ("FDA") is planning to convene an Advisory Committee meeting to discuss the Company's Biologics License Application ("BLA") seeking approval of Deramiocel, an investigational cell therapy for the treatment of Duchenne muscular dystrophy ("DMD")." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1133869/000110465926078327/capr-20260626x8k.htm)) |
| Jun 2026 | [Moderna, Inc. FDA advisory committee meeting](https://sec-api.dev/companies/mrna/catalysts) | MRNA | influenza disease in adults 50 | completed, positive | "In June 2026, the U.S. Food and Drug Administration's (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC) voted unanimously that the benefits of mRNA-1010 outweigh its risks for the prevention of influenza disease in adults 50 through 64 years of age and in adults 65 years of age and older." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1682852/000168285226000150/mrna-20260630.htm)) |

## Feeds and downloads

- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "FDA advisory committee calendar." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/adcom-calendar

```bibtex
@misc{secapidev_adcom_calendar_20261116,
  title        = {FDA advisory committee calendar},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/adcom-calendar}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_adcom_calendar_20261116","title":"FDA advisory committee calendar","publisher":"sec-api.dev","URL":"https://sec-api.dev/adcom-calendar","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
